




PHARMACEUTICAL 2021

Dicerna Pharmaceuticals Inc
Rank 276 of 402





PHARMACEUTICAL 2021

Dicerna Pharmaceuticals Inc
Rank 276 of 402

The relative strengths and weaknesses of Dicerna Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dicerna Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Dicerna Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 124% points.

The company's Economic Capital Ratio, given in the ranking table, is 19%, being 28% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	618,703
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	177,938
Liabilities, Non-Current	392,154
Other Assets	89,143
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	461
Other Revenues	164,307
Property and Equipment	0
Research and Development	205,384
Selling, General and Administrative Expense	72,131

Output Variable	Value in 1000 USD
Assets	707,846
Liabilities	570,092
Expenses	277,515
Revenues	164,307
Stockholders Equity	137,754
Net Income	-112,747
Comprehensive Net Income	-112,747
Economic Capital Ratio	19%